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Abstract [limit: 250 words; word count: 248] 22 
Streptococcus suis is one of the most important zoonotic bacterial pathogens of 23 
pigs causing significant economic losses to the global swine industry. S. suis is 24 
also a very successful coloniser of mucosal surfaces and commensal strains can 25 
be found in almost all pig populations worldwide, making detection of the S. suis 26 
species in asymptomatic carrier herds of little practical value in predicting the 27 
likelihood of future clinical relevance. The value of future molecular tools for 28 
surveillance and preventative health management lies in the detection of strains 29 
that genetically have increased potential to cause disease in presently healthy 30 
animals. Here we describe the use of genome-wide association studies to identify 31 
genetic markers associated with the observed clinical phenotypes i) invasive 32 
disease or ii) asymptomatic carriage on the palatine tonsils of pigs on UK farms. 33 
Subsequently we designed a multiplex-PCR to target three genetic markers that 34 
differentiated 115 S. suis isolates into disease-associated and non-disease 35 
associated groups; performing with a sensitivity of 0.91, specificity of 0.79, 36 
negative predictive value of 0.91, and positive predictive value of 0.79 in 37 
comparison to observed clinical phenotypes. We describe evaluation of our 38 
pathotyping tool, using an out-of-sample collection of 50 previously 39 
uncharacterised S. suis isolates, in comparison to existing methods used to 40 
characterise and subtype S. suis isolates. In doing so, we show our pathotyping 41 
approach to be a competitive method to characterise S. suis isolates recovered 42 
from pigs on UK farms, and one that can easily be updated to incorporate global 43 
strain collections.  44 
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Streptococcus suis (S. suis) is one of the most important bacterial pathogens of 46 
pigs causing significant economic losses to the swine industry worldwide (1). 47 
The infectious agent is responsible for a wide range of clinical manifestations, 48 
including septicaemia with sudden death, meningitis, endocarditis, arthritis, and 49 
pneumonia amongst other diseases (2). S. suis is also a zoonotic pathogen 50 
associated with exposure to pigs or pork-derived products (3). Although cases in 51 
Europe are infrequently reported, in recent years the surveillance and number of 52 
reported human infections has increased substantially in Southeast Asia (4-9). 53 
Importantly, S. suis is not only an invasive pathogen but also a very 54 
successful coloniser of mucosal surfaces (10). In fact, the upper respiratory tract 55 
of pigs, in particular the palatine tonsils, is considered to be both the natural 56 
habitat of S. suis and a principal route of invasion; although the bacterium can 57 
also be recovered from the gastrointestinal and genital tracts (2). Colonisation of 58 
adult pigs is common in almost all pig populations sampled, meaning that 59 
transfer of S. suis from sow to piglet during parturition and suckling is an 60 
important route of transmission (10). 61 
Several methods exist to investigate strain diversity and identify 62 
phylogenetic groups of S. suis. Simple biochemical tests cannot always 63 
differentiate S. suis from S. suis-like strains when performed on cultured isolates 64 
recovered from diseased animals, and to date remain of little practical use in 65 
differentiating invasive disease-associated strains from asymptomatic 66 
commensal-like strains both of which may contribute sub-clinically to the 67 
respiratory microflora of colonised pigs (1). Other existing methods used to 68 
characterise and subtype S. suis as part of epidemiological studies have recently 69 
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been the subject of a comprehensive review by Xia et al. (11). Each approach has 70 
its limitations often requiring either large amounts of sample DNA, which is 71 
labour intensive and cumbersome, or high levels of technical competence making 72 
the comparison of results between laboratories difficult. 73 
To date, serotyping remains the most widely used method to subtype 74 
S. suis isolates and is an important part of the routine diagnostic procedure (2, 75 
12). A total of 35 serotypes have been described for S. suis based on differences 76 
in the capsular polysaccharide antigens, but since their original descriptions 77 
evidence now exists for the reclassification of a number of serotypes as other 78 
Streptococcus species meaning current opinion considers there to be just 29 79 
"true" S. suis serotypes (namely 1-19, 21, 23-25, 27-31, and 1/2) (13). Serotype 2 80 
predominates among clinical cases of disease in most countries, although 81 
serovars 1-9, 14 & 1/2 have all been documented as being of clinical importance 82 
in certain geographical locales (14-18). As a result, serotyping has been used as a 83 
proxy for predicting the virulence potential of S. suis isolates. However, the use of 84 
serotyping alone as a predictor of virulence has the limitation that strains of the 85 
same serotype can vary substantially in virulence (19, 20). 86 
Given the limitations of serotyping to reliably predict virulence potential 87 
of S. suis strains other markers have been investigated. A wide range of homologs 88 
of bacterial virulence factors and virulence-associated factors found in other 89 
Gram-positive organisms has been shown to affect the virulence of S. suis strains 90 
through targeted mutagenesis studies (21-23). However, clear association with 91 
specific roles in the onset and development of disease has not been found for 92 
many proposed factors (24, 25). Despite this, the 'virulence-associated markers' 93 
(rather than virulence factors per se) extracellular protein factor (EF, encoded by 94 
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the epf gene) (26) and muramidase-released protein (MRP, encoded by the mrp 95 
gene) (27), as well as, the thiol-activated toxin hemolysin, suilysin (SLY, encoded 96 
by the sly gene) (28, 29) have been extensively used to predict the virulence 97 
potential of S. suis strains in certain mainly European countries, particularly for 98 
strains of serotype 2 (17, 24, 30). Unfortunately, genotyping of epf, mrp, and/or 99 
sly also fails to provide clear classification of a S. suis isolate as virulent (or not) 100 
because isogenic mutants devoid of such factors have been found to be as 101 
virulent as their respective parental strains, emphasising the importance of their 102 
consideration as virulence associated markers rather than true virulence factors 103 
per se (31). 104 
Advances in sequencing technologies now allow whole-genome 105 
sequencing (WGS) of multiple strains of the same species, including S. suis (32-106 
36). This explosion in the amount of detailed genetic information has allowed 107 
Bayesian analysis of population structure and the investigation of S. suis 108 
recombination rates, revealing enormous species diversity and significant 109 
genomic differences between S. suis isolates responsible for systemic disease in 110 
pigs when compared to non-clinical isolates recovered from the upper 111 
respiratory tract (35). Indeed, in 2015 Weinert et al. proposed loss of protein-112 
encoding sequences had led to a smaller systemic disease-associated genome 113 
with increased virulence potential and an overrepresentation of genes encoding 114 
previously reported virulence-factors associated with S. suis (35). 115 
Minimum core genome (MCG) sequence typing is a recently described 116 
typing scheme that also takes advantage of the increase in available S. suis WGS 117 
data, using population genetics-based sub-divisions for strain identification and 118 
typing (33, 37). MCG sequence typing exploits advances in next-generation 119 
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sequencing to identify novel regions of the core-genome that can be used to 120 
identify and type S. suis isolates into "MCG groups" that can later be associated 121 
with clinical phenotypes. In fact, during its design, MCG group 1 was reported as 122 
being assigned to all highly virulent isolates tested and associated with the 123 
greatest occurrence of previously reported virulence genes (33). However, MCG 124 
sequence typing like multilocus sequence typing (MLST), also described for 125 
S. suis (38), is difficult to apply to routine diagnostic testing and can sometimes 126 
lack the discriminatory power to differentiate bacterial strains into virulent and 127 
avirulent sub-populations, limiting its usefulness in epidemiological studies. 128 
The aim of this study was to design and then evaluate a pathotyping tool 129 
to predict the virulence potential of S. suis isolates using genome-wide 130 
association studies, a so-far unexploited method for the identification of S. suis 131 
virulence-associated markers. The statistical power to allow the identification of 132 
robust associations between genotype and phenotypes including virulence in 133 
many different bacterial species is now possible due to the rapid increases in the 134 
availability of detailed WGS data (39, 40). Here we have combined WGS data 135 
with high-quality clinical metadata in order to identify genetic markers in the 136 
S. suis accessory genome (i.e. genes absent from one or more isolates or unique 137 
to a given isolate) associated with i) invasive disease or ii) asymptomatic 138 
carriage on the palatine tonsils of pigs on UK farms. Subsequently, we designed a 139 
multiplex-PCR (mPCR) to target three genetic markers that differentiated 115 140 
S. suis isolates into i) invasive disease-associated and ii) non-disease associated 141 
groups. We also describe evaluation of our pathotyping tool (generalised linear 142 
model and mPCR), using an out-of-sample collection of 50 previously 143 
uncharacterised S. suis isolates, in comparison to existing methods used to 144 
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characterise and subtype S. suis isolates. In doing so, we show our approach to be 145 
a competitive method to subtype S. suis isolates recovered from pigs on UK 146 
farms, and one that can easily be updated to incorporate global strain collections. 147 
  148 
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Materials and Methods 149 
Bacterial isolates. Two groups of S. suis isolates were used in this study a) a 150 
training collection of 115 isolates and b) an out-of-sample test collection of 50 151 
previously uncharacterised isolates. The original training collection was used 152 
to identify genetic markers which could differentiate S. suis isolates into i) 153 
invasive disease-associated and ii) non-disease associated phenotypic groups. 154 
The 'training' collection consisted of laboratory reference strain P1/7 155 
(NC_012925) originally recovered from an ante-mortem blood culture from a pig 156 
that died with meningitis in the United Kingdom (32, 41). The other 114 isolates 157 
of the training collection were a subset recovered from pigs on farms in England 158 
and Wales during routine diagnostic investigations at the Animal Health and 159 
Veterinary Laboratories Agency (AHVLA; now the Animal and Plant Health 160 
Agency, APHA) in 2010, and contribute to a larger collection previously 161 
described in 2015 by Weinert et al. (35). Well-defined phenotypic metadata were 162 
available based on which each isolate was categorised as being associated with 163 
invasive S. suis disease (n=53; recovered from systemic sites in the presence of 164 
clinical signs (arthritis, meningitis, septicaemia) and/or gross pathology 165 
consistent with S. suis infection) or as being non-disease associated (n=62; 166 
recovered from the tonsil or trachea-bronchus of pigs without any typical signs 167 
of streptococcal disease but diagnosed with disease unrelated to S. suis, such as 168 
enteric disease). The out-of-sample test collection was used to evaluate our 169 
pathotyping tool. Out-of-sample forecasting is a common approach used to 170 
evaluate the performance of binary diagnostic tests. To avoid reducing statistical 171 
power, rather than split the training collection, an additional out-of-sample ‘test’ 172 
collection was put together consisting of 23 invasive disease-associated 173 
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(recovered from systemic, non-respiratory locations of pigs diagnosed with 174 
S. suis disease at the APHA during 2013) and 27 non-disease associated isolates 175 
(recovered from material scraped from the palatine tonsils of pigs exhibiting no 176 
signs of S. suis disease on farms in England and Wales between June 2013 and 177 
May 2014). Site of recovery, ante-, and post-mortem findings of all isolates 178 
described in this study are summarised in Table S1. 179 
Identification of genetic markers associated with observed clinical 180 
phenotype. Genetic markers to pathotype S. suis were identified using positive 181 
detection data of putative protein-encoding sequences making up the S. suis 182 
accessory-genome (i.e. genes absent from one or more isolates or unique to a 183 
given isolate). The accessory genome was taken from Weinert et al. (35). Briefly, 184 
de novo assemblies of Illumina fastq reads were produced, protein-encoding 185 
genes were then identified and used in MCL clustering to find orthologue groups, 186 
which were manually checked. Two complementary genome-wide association 187 
studies i) the univariate Chi-squared test for independence and ii) the 188 
multivariate Discriminant Analysis of Principal Components (DAPC) were 189 
combined to define a preliminary list of genetic markers associated with the 190 
observed clinical phenotypes i) invasive disease or ii) asymptomatic carriage on 191 
the palatine tonsils of pigs. The Chi-squared test for independence, implemented 192 
in the R package: stats (42), was used to compare the observed positive 193 
detection of protein-encoding sequences with expected frequencies, in doing so 194 
calculating a test statistic that if greater than the critical value was reason 195 
enough to reject the null hypothesis of independence (p-value <0.05). Bonferroni 196 
adjustment (α/n) was used to control for family-wise error associated with 197 
multiple sampling. 198 
 o
n






DAPC (43, 44), implemented in the R package: adegenet (45, 46), was 199 
used to identify genetic differences between pre-defined phenotypic groups. The 200 
total amount of original variation retained in the DAPC model affected which 201 
genetic markers contributed most to the separation of genetic structures. As a 202 
result, four independent DAPC analyses were performed retaining 60, 70, 80 or 203 
90% of the original genetic variation, and the 1% of ranked genetic markers 204 
contributing most to the discrimination of pre-defined phenotypic groups was 205 
then analysed and genetic markers consistently output by two or more DAPC 206 
analyses taken forward as candidates for pathotyping S. suis. 207 
Analysis of the distribution of previously reported virulence factors 208 
associated with S. suis disease. Protein-encoding sequences present in P1/7, 209 
taken from the list of previously published virulence and virulence-associated 210 
factors complied as part of a comprehensive review by Fittipaldi et al. (24), were 211 
extracted from GenBank (Table S2). P1/7 protein-encoding sequences were used 212 
as tBLASTn queries against a bespoke BLAST database consisting of the draft 213 
genome assemblies of all isolates described in this study. Amino acid level 214 
matches to >80% of >80% of the total length of each translated protein-encoding 215 
sequence were considered hits. 216 
Selection of genetic markers to pathotype S. suis. Logistic regression 217 
analysis in the form of a generalised linear model (GLM) with backwards-218 
stepwise selection using penalised likelihood ratio tests, implemented in the R 219 
package: logistf (47), was used to identify the fewest statistically significant (p-220 
value <0.05) markers to differentiate S. suis isolates into pre-defined i) invasive 221 
disease-associated and ii) non-disease associated groups. A receiver operating 222 
characteristic (ROC) curve, implemented in the R package: ROCR (48), was used 223 
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to visualise the GLM performance metrics true positive rate (sensitivity) and 224 
false positive rate (1-specificity) in comparison to the observed clinical 225 
phenotype (considered to be the ‘gold-standard’ in this study), and a cutoff 226 
threshold selected to convert the real-valued output (fitted values) of the logistic 227 
regression (probability of causing invasive disease) into a binary class decision: 228 
invasive disease-associated (1)/non-disease associated (0). As no cutoff was 229 
optimal according to all possible performance criteria, cutoff choice involved a 230 
trade-off between different performance metrics where low false negative rate 231 
(1-sensitivity, analogous to Type II error) was chosen as the most valuable 232 
performance metric for pathotyping S. suis, with a view to establish and then 233 
maintain a pig population free of invasive disease-associated strains. 234 
All statistical analyses were performed using the standard R environment 235 
for statistical computing and graphs (version 3.1.1) (49). 236 
Identification of S. suis-species specific genetic markers. We designed 237 
a mPCR to target genetic markers associated with observed clinical phenotype, 238 
along with a S. suis species-specific marker as a positive control. The most 239 
conserved protein-encoding sequences of the S. suis core-genome (i.e. present in 240 
all isolates) were used to select a species-specific marker to complement the 241 
pathotyping markers. To do this, all annotated protein-encoding sequences of 242 
S. suis strain P1/7 were used as BLASTn queries against a bespoke BLAST 243 
database of all de novo assemblies and known S. suis complete genome 244 
sequences. Protein-encoding sequences with identities >95% across >80% of the 245 
total length of each query sequence were then used to query the NCBI non-246 
redundant (nr) database to identify matches only to S. suis. 247 
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Multiplex-PCR and detection of PCR amplicons. The online software, 248 
primer3 version 4.0.0 (http://primer3.ut.ee) was used to design mPCR primers. 249 
All mPCR primers were designed to target conserved regions within the protein-250 
encoding sequence of genetic markers (as opposed to flanking regions) and are 251 
summarised in Table 1. Primers were designed to have similar physical 252 
characteristics, enabling simultaneous amplification under the same thermal 253 
cycling conditions and in multiplex reactions. Primer length (21-30 bp), GC 254 
content (40-60%), melting temperature (>68 ˚C if possible, but at least 60 ˚C), 255 
and expected amplicon size (100-1000 bp) were based on the manufacturer’s 256 
recommendations for primer design using the Multiplex PCR Plus kit (Qiagen). 257 
Consistency between the positive detection of genetic markers and primer 258 
matches was investigated using BLASTn. Prior to ordering, all primers were 259 
queried against the NCBI nr nucleotide database to check for non-S. suis DNA 260 
matches. Primers were synthesised by Sigma-Aldrich (Haverhill, United 261 
Kingdom) and delivered in solution (TE buffer; 10 mM Tris-Cl, 1 mM EDTA [pH 262 
8.0]) at a stock concentration of 100 μM; primers were used at a working stock 263 
concentration of 20 μM. 264 
All mPCRs were performed using the Multiplex PCR Plus Kit (Qiagen), and 265 
unless otherwise stated contained the same reagents except for template DNA. 266 
The reaction mixture (50 μl) for each mPCR consisted of 25 μl 2x Multiplex PCR 267 
Master Mix, 5 μl 10x CoralLoad Dye, 10 μl RNase-free water, 0.2 μM (final 268 
concentration) of each primer, and 10 ng template DNA. The three-step thermal 269 
cycling program for all reactions was as follows: 95 ˚C for 5 min, followed by 35 270 
cycles of (denaturation) 95 ˚C for 30 s, (annealing) 66 ˚C for 90 s, and (extension) 271 
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72 ˚C for 90 s; with a final extension of 68 ˚C for 10 min using a T100 Thermal 272 
Cycler (Bio-Rad). 273 
PCR products were analysed by gel electrophoresis using 2% (wt/vol) 274 
UltraPure Agarose (Invitrogen) gels made with 1x TBE buffer, and contained 1x 275 
SYBR Safe DNA gel stain (Invitrogen). Running time was 60 min at a constant 276 
100 V. Results were visualised using a GelDoc imager (BioRad). Where 277 
appropriate, mPCR products were purified using the QIAquick PCR Purification 278 
Kit (Qiagen) as per the manufacturer’s instructions and Sanger sequenced using 279 
the Source Bioscience Lifesciences sequencing service. Returned sequencing data 280 
was aligned with reference sequences of the target protein-encoding sequence 281 
using CodonCode Aligner software (CodonCode Corporation). 282 
The approximate limit of detection of the mPCR was estimated from 10-283 
fold serial dilutions of S. suis genomic DNA of known concentration. DNA 284 
extracted from four isolates of the training collection representing invasive 285 
disease-associated (SS002 and SS004) and non-disease associated (LSS011 and 286 
LSS027) phenotypes/genotypes was mixed in equal quantities so that templates 287 
for each mPCR amplicon would be present in all reactions. A series of 10-fold 288 
dilutions were then performed to create mPCR templates of decreasing 289 
concentration. The limit of detection was considered to be the lowest 290 
concentration of template DNA from which all predicted mPCR amplicons, after 291 
35 thermal cycles, were easily visible under UV transillumination. 292 
To evaluate the specificity of the mPCR assay for S. suis, field isolates of 293 
Streptococcaceae commonly recovered from the upper respiratory tract of pigs 294 
on farms in England and Wales were used as a panel of negative controls. The 295 
collection included isolates of Streptococcus gallolyticus, Streptococcus orisratti, 296 
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Streptococcus pneumoniae, and Streptococcus uberis, sourced from BBSRC 297 
research project: BB/L003902/1. In addition, commensal Pasteurellaceae 298 
including Actinobacillus indolicus, Actinobacillus minor, Actinobacillus porcinus, 299 
and Haemophilus parasuis (Nagasaki and SW140) were also included, as well as 300 
DNA from an Alcaligenaceae isolate of Bordetella bronchiseptica RB50 301 
(NC_002927) (50). 302 
Comparison of our pathotyping tool to existing methods used to 303 
subtype disease-associated isolates of S. suis. To compare our pathotyping 304 
tool (GLM and mPCR) to published methods used to subtype disease-associated 305 
isolates of S. suis, the molecular serotype, virulence-associated gene (epf, mrp, 306 
and sly) profile, MLST, and MCG sequence type were all determined in silico. For 307 
comparison of our pathotyping tool against each existing method the original 308 
training collection was used to ‘train’ a model that was then applied to the out-309 
of-sample ‘test’ collection. 310 
Traditional serotyping (by capillary precipitation) data was unavailable 311 
for all S. suis isolates described in this study, therefore, molecular ‘serotyping’ 312 
was performed using an adaptation (for in silico use) of the mPCR assays 313 
described by Liu et al. (51). Primer sequences were used as BLASTn queries and 314 
nucleotide level matches to >95% of the total length of each primer sequence 315 
were considered hits. The distance between hits was compared to reported PCR 316 
amplicon sizes. Isolates that could not be assigned to one of the 35 (1-34 & 1/2) 317 
originally described S. suis serotypes were deemed non-serotypable (NT). 318 
Differentiation of molecular ‘serotypes’ 1 from 14 and 2 from 1/2 was performed 319 
using the published method described by Athey et al. (52).  All isolates, in 320 
particular those deemed to be NT, were confirmed to be S. suis using a 321 
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combination of i) biochemical profile (API 20 Strep), ii) MLST data, and iii) recN 322 
sequence homology (53). 323 
Virulence-associated gene profiling was performed using an adaptation 324 
(for in silico use) of the method described by Silva et al. (54). Again mPCR and 325 
singleplex-PCR primer sequences were used as BLASTn queries and nucleotide 326 
level matches to >95% to the total length of each primer sequence were 327 
considered hits. The distance between hits compared to reported PCR amplicon 328 
sizes. Logistic regression (as described above) using the prevalence of epf, mrp, 329 
and/or sly as the GLM explanatory variables was used to classify all isolates as i) 330 
invasive disease-associated or ii) non-disease associated. 331 
MLST was performed using the online software MLST version 2.0 332 
(http://cge.cbs.dtu.dk) (55). 333 
MCG sequence typing was performed using an adaptation (for in silico 334 
use) of the method described by Zheng et al. (37). Multiplex-PCR primer 335 
sequences were used as BLASTn queries and nucleotide level matches to >95% 336 
of the total length of each primer sequence were considered hits. The distance 337 
between hits compared to reported mPCR amplicon sizes. Nucleotide sequences 338 
between primer sequence matches were then extracted, aligned against the MCG 339 
typing reference strain GZ1 (GenBank: CP000837), and the 10 SNPs of interest 340 
called allowing isolates to be assigned to one of the seven reported MCG groups 341 
for S. suis. 342 
McNemar’s Chi-squared Test for Count Data, implemented in the R 343 
package: stats (42), was used to test for statistically significant differences in the 344 
sensitivities and specificities of two binary diagnostic tests in a paired study. The 345 
Weighted Generalised Score Statistic for Comparison of Predictive Values as 346 
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proposed by Kosinski (56), implemented in the R package: DTComPair (57), was 347 
used to test for significant differences in (negative and positive) predictive 348 
values of two binary diagnostic tests.  349 
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Design of a pathotyping tool for S. suis. Genetic markers to pathotype S. suis 351 
were identified using positive detection data of 7261 putative protein-encoding 352 
sequences making up the S. suis accessory-genome (35). To do this, the output of 353 
two complementary genome-wide association studies were combined to define a 354 
preliminary list of 497 genetic markers associated with the observed clinical 355 
phenotypes i) invasive disease or ii) asymptomatic carriage on the palatine 356 
tonsils of pigs. A multistep process was used to reduce the preliminary list to a 357 
number suitable for logistic regression analysis, retaining genetic markers only if 358 
i) positively detected in >50% of invasive disease-associated and <50% of non-359 
disease associated isolates (and vice versa <50% of invasive disease-associated 360 
and <50% of non-disease associated isolates; n=88 remaining), ii) protein-361 
encoding sequence length was >500 bp (based on the manufacturer’s 362 
recommendations for primer design using the Qiagen Multiplex PCR Plus kit; 363 
n=44 remaining), and iii) not predicted to be a mobile genetic element, such as a 364 
phage gene, integrase or transposon (based on Prokka annotations; n=14 365 
remaining). A GLM with backwards-stepwise selection using penalised likelihood 366 
ratio tests was then used for the final selection of genetic markers, two 367 
associated with invasive disease and one associated with asymptomatic carriage 368 
(Table 1). A receiver operating characteristic (ROC) curve was used to visualise 369 
the GLM performance metrics true positive rate (sensitivity) and false positive 370 
rate (1-specificity), and select the cutoff threshold of 0.43 to be used to convert 371 
the real-valued output (fitted values) of the GLM into a binary class decision: 372 
invasive disease-associated/non-disease associated (Table S1). In comparison to 373 
the observed clinical metadata, considered the ‘gold-standard’ in this study, our 374 
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three genetic markers subtyped the 115 S. suis isolates of the training collection 375 
with a sensitivity of 0.91, specificity of 0.79, negative predictive value of 0.91, 376 
and positive predictive value of 0.79 (Table S3(a)). 377 
At present, WGS is not readily available for routine surveillance studies in 378 
veterinary diagnostics laboratories, therefore, we designed a mPCR to target the 379 
three genetic markers selected to pathotype S. suis. In addition to genetic 380 
markers selected to differentiate S. suis isolates into i) invasive disease-381 
associated and ii) non-disease associated groups, we also incorporated a S. suis 382 
species-specific marker into our mPCR assay. To do this, we first identified the 383 
most conserved protein-encoding sequences contributing to the S. suis core 384 
genome (i.e. present in all isolates) and selected SSU0577 as a novel S. suis 385 
species-specific marker, that had a minimum nucleotide sequence identity of 386 
98.15% across the total length of the 918 bp protein-encoding sequence. 387 
Evaluation of our pathotyping mPCR with the original training 388 
collection. Figure 1 shows an example of the mPCR amplicon patterns after gel 389 
electrophoresis on a 2% (wt/vol) agarose gel and photographed under UV 390 
transillumination. Amplicons of size 722 bp correspond to the S. suis species-391 
specific marker (SSU0577), and were produced by all isolates of the training 392 
collection irrespective of invasive disease-associated/non-disease associated 393 
phenotype or genotype. Other amplicons, of size 211 bp and 347 bp correspond 394 
to the invasive disease-associated markers SSU0207 and SSU1589 respectively, 395 
and amplicons of size 892 bp correspond to the non-disease associated marker 396 
SSUST30534. 397 
To determine the analytical sensitivity of the mPCR the approximate limit 398 
of detection was estimated from 10-fold serial dilutions of S. suis genomic DNA of 399 
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known concentration. The limit of detection was estimated to be ~0.0001 ng of 400 
S. suis genomic DNA (equivalent to ~45 genome copies), the lowest 401 
concentration of template DNA from which all predicted mPCR amplicons, after 402 
35 thermal cycles, were easily visible under UV transillumination (data not 403 
shown). 404 
To evaluate the specificity of our mPCR for S. suis, field isolates of 405 
Streptococcaceae, Pasteurellaceae, and Alcaligenaceae commonly recovered 406 
from the upper respiratory tract of pigs on farms in England and Wales were 407 
used as a panel of negative controls. No mPCR amplicons, after 35 thermal cycles 408 
and gel electrophoresis, were visible under UV transillumination for any of the 409 
panel of ten negative controls (data not shown). 410 
Evaluation of our pathotyping tool with an out-of-sample collection. 411 
Further evaluation of our pathotyping tool (GLM and mPCR) was done using an 412 
out-of-sample test collection of 50 previously uncharacterised (genetically) 413 
S. suis isolates (23 invasive disease-associated and 27 non-disease associated). 414 
Template DNA extracted from each of the 50 isolates produced the 722 bp mPCR 415 
amplicon corresponding to the S. suis species-specific marker SSU0577. For each 416 
isolate, the presence/absence of mPCR amplicons was then input into the GLM 417 
and the cutoff threshold of 0.43 applied to the fitted-values to generate the 418 
binary classification decision. Table 2(a) summarises the classification of the out-419 
of-sample test collection isolates in comparison to the observed clinical 420 
metadata, resulting in a sensitivity of 0.83, specificity of 1.00, negative predictive 421 
value of 0.87, and positive predictive value of 1.00. 422 
Comparison of our pathotyping tool to existing methods used to 423 
subtype disease-associated isolates of S. suis. To compare our pathotyping 424 
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tool to the use of serotype as a proxy to predict the virulence potential of S. suis 425 
isolates, the serotypes most frequently recovered from diseased pigs (1-9, 14 & 426 
1/2) were considered a marker of disease association and all other serotypes 427 
considered markers of non-disease association. Table 2(b) summarises the 428 
classification of the out-of-sample test collection isolates in comparison to the 429 
observed clinical metadata, and shows the use of molecular serotypes 1-9, 14 & 430 
1/2 to predict disease-association performed with a sensitivity of 0.87 (n=3 type 431 
II errors), not statistically different from our new mPCR pathotyping tool 432 
(McNemar’s Chi-squared test for count data p-value = 0.31731). Other 433 
performance metrics for the molecular serotype-based approach were a 434 
significantly worse positive predictive value of 0.77 (weighted generalised score 435 
statistic for comparison of predictive values p-value = 0.01149) and a 436 
significantly worse specificity of 0.78 (n=8 type I errors, McNemar’s Chi-squared 437 
test for count data p-value = 0.01431); no statistically significant difference in 438 
negative predictive value was observed (weighted generalised score statistic for 439 
comparison of predictive values p-value = 0.90553). 440 
To compare our pathotyping tool to the use of epf, mrp and/or sly for the 441 
identification of virulent S. suis strains, first a GLM was fitted to the prevalence 442 
data of these virulence-associated genes in the original ‘training’ collection of 443 
S. suis isolates and, using the same selection criteria as previously described for 444 
the pathotyping markers, a ROC curve used to select the cutoff of 0.12 to convert 445 
the GLM fitted values into a binary class decision. The predict function, 446 
implemented in the R package: logistf (47), was then used to generate fitted 447 
values for the isolates in the out-of-sample test collection (Table S1). Table 2(c) 448 
summarises the classification of the out-of-sample test collection isolates as 449 
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invasive disease-associated/non-disease associated based on the positive 450 
detection of epf, mrp and/or sly in comparison to the observed clinical 451 
phenotype. The combined virulence-associated markers performed with a 452 
sensitivity of 0.96 (n=1 type II errors), again not statistically different from our 453 
new mPCR pathotyping tool (p-value = 0.08326). Other performance metrics for 454 
the virulence-associated genotyping approach were a significantly worse 455 
positive predictive value of 0.46 (p-value = 2.97708e-7; incidentally performing 456 
no better than chance (Exact binomial test p-value = 1)), and a significantly 457 
worse specificity of 0.04 (p-value = 3.41417e-7). The negative predictive value 458 
was calculated to be 0.50, worse but not a statistically significant difference (p-459 
value = 0.07853). 460 
We compared our pathotyping tool to the use of the King et al. MLST 461 
scheme (38) as a proxy to predict the virulence potential of S. suis isolates. 462 
Sequence type (ST) 1 was assigned to 70% of disease-associated isolates and 3% 463 
of non-disease associated isolates of the training collection (Table S1). As ST1 is 464 
mostly associated with disease in both pigs and humans in Europe (12) we used 465 
assignment to ST1 as a binary classifier to indicate disease-association in 466 
comparison to the observed clinical metadata. Table 2(d) summarises the 467 
classification of the out-of-sample test collection isolates as invasive disease-468 
associated/non-disease associated based on the assignment toST1 in 469 
comparison to the observed clinical phenotype. Assignment to ST1 performed 470 
with a sensitivity of 0.70 (n=7 type II errors), worse in comparison to our 471 
pathotyping tool but not a statistically significant difference (p-value = 0.08326). 472 
The negative predictive value was calculated to be 0.79, again worse but not a 473 
statistically significant difference (p-value = 0.08294). Other performance 474 
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metrics (specificity and positive predictive value) were found to be identical in 475 
comparison to our pathotyping tool. 476 
Finally, we compared our pathotyping tool to the use of the Zheng et al. 477 
MCG typing scheme (33, 37), one of the most recent typing schemes that exploits 478 
advances in next-generation sequencing to identify virulent S. suis strains. MCG 479 
group 1 was assigned to 77% of disease-associated isolates and 3% of non-480 
disease associated isolates of the training collection (Table S1). Together with 481 
the report of MCG group 1 being assigned to all highly virulent isolates tested 482 
during design of the typing scheme (33), we used assignment to MCG group 1 as 483 
a binary classifier to indicate disease-association; performance in comparison to 484 
the observed clinical metadata is summarised in Table 2(e). Assignment to MCG 485 
group 1 performed with a sensitivity of 0.78 (n=5 type II errors), again worse in 486 
comparison to our pathotyping tool but not a statistically significant difference 487 
(p-value = 0.31731). The negative predictive value was calculated to be 0.84, also 488 
worse but not a statistically significant difference (p-value = 0.31725). Other 489 
performance metrics (specificity and positive predictive value) were found to be 490 
identical in comparison to our pathotyping tool. 491 
.  492 
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We have described the design of a pathotyping tool (GLM and mPCR) exploiting 494 
the identification of genetic markers in the S. suis accessory-genome (i.e. genes 495 
absent from one or more isolates or unique to a given isolate) associated with 496 
the observed clinical phenotypes i) invasive disease or ii) asymptomatic carriage 497 
on the palatine tonsils of pigs on UK farms. Initial analyses of the original 498 
training collection were unable to identify any single genetic marker of invasive 499 
disease prevalent in >95% of invasive disease-associated isolates and not 500 
positively identifiable in <5% of non-disease associated isolates. Furthermore, 501 
we found over half (n=40) of published putative "virulence-factors", extracted 502 
from the previous comprehensive review by Fittipaldi et al. (24) and present in 503 
P1.7, did not show a strong relationship with observed clinical phenotype as they 504 
were either i) positively detected in the S. suis core-genome (i.e. prevalent in all 505 
isolates; n=38) or ii) not detected by our methods in any of the 115 isolates of 506 
the training collection (n=2; data not shown). The reason for this is unclear, 507 
although could be an effect of previous studies being limited to small numbers of 508 
isolates often restricted to serotype 2 (58), and of varied and inconsistent animal 509 
models between research groups (25). 510 
To avoid restricting our analyses to previously published reports and not 511 
taking full advantage of the statistical power of our WGS data set, we used two 512 
complementary genome-wide association studies and then logistic regression 513 
analysis for the final selection of genetic markers to pathotype S. suis. Using 514 
logistic regression analysis also allowed for the possibility that multiple genetic 515 
markers might best describe the S. suis pathotype. Our pathotyping markers 516 
assigned the 115 S. suis isolates of the original training collection to phenotypic 517 
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groups (disease-associated/non-disease associated) with a sensitivity of 0.91 i.e. 518 
the proportion of isolates recovered from systemic sites and predicted to be 519 
disease causing isolates. A specificity of 0.79 i.e. the proportion of isolates 520 
recovered from the upper respiratory tract of pigs without any typical signs of 521 
S. suis infection and predicted to be non-disease associated isolates. A negative 522 
predictive value of 0.91 i.e. the proportion of isolates predicted to be non-disease 523 
associated that were actually recovered from the upper respiratory tract of pigs 524 
without any typical signs of S. suis infection. As well as, a positive predictive 525 
value of 0.79 i.e. the proportion of isolates predicted to be associated with 526 
invasive disease that were actually recovered from a systemic site. 527 
An important caveat of our pathotyping tool design is consideration of the 528 
observed clinical phenotype associated with each isolate as the ‘gold standard’ to 529 
characterise S. suis isolates as disease-associated or non-disease associated. In 530 
the absence of an agreed superior approach, clinical metadata was used to assign 531 
S. suis isolates to one of two phenotypic groups and it is acknowledged that such 532 
an approach is not perfect as not all additional factors can be accounted for, such 533 
as host-immune status, concurrent infections, or environmental conditions that 534 
could influence the susceptibility of a host to S. suis-associated disease. Indeed, 535 
reports of in vivo challenge studies can be readily found in the S. suis literature, 536 
although most describe data limited to a small number of isolates, often 537 
restricted to serotype 2 (58), and under very different conditions making the 538 
extrapolation of findings difficult to interpret. An ideal standard would require 539 
an agreed panel of isolates for which a series of consistently controlled 540 
experimental infection challenge studies had been undertaken using pigs of 541 
identical immune status and genetics. However, in order for this to happen 542 
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experts in the field must first agree on a suitable model and set of well-defined 543 
criteria to score virulence (25, 59, 60). 544 
Another important caveat of our pathotyping tool design is the source of 545 
S. suis isolates of the original training collection that were deemed to be non-546 
disease associated. While all efforts were made to accurately define invasive 547 
disease-associated and non-disease associated phenotypic groups it should be 548 
acknowledged that non-disease associated isolates of the original training 549 
collection were recovered from routine submissions to the APHA in 2010 and 550 
that these pigs were not healthy, even though they did not show signs of typical 551 
streptococcal disease; instead clinical features were consistent with different 552 
non-infectious diseases or disease caused by other non-S. suis infectious agents. 553 
Indeed, 13 isolates of the original training collection deemed to be non-disease 554 
associated by phenotype were predicted by our pathotyping tool to have the 555 
potential to cause invasive disease. These 13 type I errors (or ‘false’ positives) in 556 
comparison to the observed clinical metadata could in fact be true predictions 557 
and examples of S. suis strains with the potential to cause invasive disease being 558 
carried in the upper respiratory tract of pigs on UK farms. Therefore, it is 559 
possible that the mortality of these 13 pigs was due to clones of isolates 560 
recovered from the palatine tonsils or trachea-bronchus yet was not identified as 561 
so due to a concurrent or opportunistic infection presenting a more obvious 562 
phenotype, such as diarrhoea. Such an observation is supported by evidence in 563 
the literature reporting that virulent strains of S. suis can be isolated from the 564 
tonsils of pigs without obvious streptococcal disease (61, 62), which is likely to 565 
represent carriage of invasive disease-causing stains by pigs that have mounted 566 
an effective immune response. 567 
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We deemed the false negative rate (1-sensitivity) to be the most valuable 568 
performance metric for a S. suis pathotyping tool in order to establish and 569 
maintain a pig population free of invasive disease-associated S. suis strains. 570 
During out-of-sample testing the false negative rate of 0.17 corresponded to four 571 
false negatives (or type II errors), where non-disease associated pathotyping tool 572 
predictions were made for isolates linked with invasive disease clinical 573 
metadata. It is interesting to speculate at the reasons for such observations. 574 
Often S. suis strains are described as opportunistic or secondary pathogens that 575 
without a weakened host immune status (due to stress or concurrent infection) 576 
would normally be carried asymptomatically, contributing to the normal oral 577 
microflora of pigs. This may be the explanation for the differences observed 578 
between our pathotyping tool prediction and the observed clinical phenotype, 579 
again emphasising the fallibility of the phenotype assigned when it is based on 580 
field sampling without carefully controlled infection challenge data. 581 
Comparison to published methods revealed our molecular pathotyping 582 
tool to be a competitive method to subtype S. suis isolates, even though the 583 
necessarily small number of clinically phenotyped isolates in the out-of-sample 584 
collection limited the statistical power of the comparison. Comparing the 585 
commonly used performance metrics sensitivity, specificity, negative predictive 586 
value, and positive predictive value we found the use of i) serotypes 1-9, 14 & 587 
1/2, ii) a GLM based on the positive detection of virulence-associated markers 588 
epf, mrp and/or sly, iii) assignment to MLST 1, and iv) assignment to MCG group 589 
1 performed with statistically similar sensitivities in comparison to our 590 
pathotyping tool. However, the trade off for high sensitivities was significantly 591 
worse specificities and negative predictive values when using serotypes 1-9, 14 592 
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& 1/2 or the virulence-associated markers: epf, mrp and/or sly, in certain cases 593 
performing no better than chance (p-value =1) in comparison to our pathotyping 594 
tool. Over all, the performance of our pathotyping tool was at least statistically 595 
similar and competitive with, and in some cases, better than previously 596 
described methods for assessing the clinical significance of S. suis isolates. 597 
Similarly, performance of our newly proposed S. suis species-specific marker 598 
(SSU0577) was encouraging. An important part of our pathotyping tool, due to 599 
the presence of S. suis-like organisms such as Streptococcus orisratti in the pig 600 
upper respiratory tract, we acknowledge that the specificity of SSU0577 for 601 
S. suis and not S. suis-like organisms needs to be extended and studied further 602 
against markers such as recN. 603 
At present the role in pathogenesis of our newly defined pathotyping 604 
markers is unknown. Based on predicted biological functions (Table 1) we 605 
speculate that marker SSU0207, predicted to be a copper exporting ATPase, 606 
might allow S. suis to avoid copper toxicity inside phagocytes as copper 607 
homeostasis has been shown to be important in many bacterial species (63-65). 608 
The marker SSU1589 is annotated as a Type I restriction-modification (RM) 609 
system S protein in S. suis strain P1/7. Ubiquitous among prokaryotes, Type I RM 610 
systems are large multifunctional protein complexes thought to defend host 611 
bacterium from foreign DNA borne by bacteriophages, and have recently been 612 
described in P1/7 and S. suis strains isolated in the Netherlands (66, 67). 613 
Considered primitive immune systems in bacteria, it has been proposed that the 614 
range of functions RM systems may have should be expanded to include 615 
stabilising mobile genetic elements or gene regulation, potentially providing 616 
evolutionary fitness advantages and virulence under certain conditions (68). 617 
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Indeed, the proposed role in protection against foreign DNA may merely be a 618 
coincidental benefit of these functions (69). In fact, a Type I RM system in 619 
Streptococcus pneumoniae which can undergo genetic recombination with 620 
truncated variants of the same gene to generate alternative variants with 621 
different methylation specificities could control global changes in gene 622 
expression (70). In Streptococcus pneumoniae there is a selection for variants of 623 
this genetic switching in vivo, indicating a role in systemic disease. 624 
Our third genetic marker (SSUST30534), a putative sugar ABC 625 
transporter, was positively associated with the non-disease associated 626 
phenotype (asymptomatic commensal-like carriage). The practical application of 627 
the genetic marker positively associated with asymptomatic carriage might not 628 
be immediately obvious but its statistical significance in the GLM is noteworthy. 629 
Indeed, gene loss (of so-called 'antivirulence genes') in the evolution of bacterial 630 
pathogens from non-pathogenic commensal strains could be a mechanism of fine 631 
tuning pathogen genomes for maximal fitness in new host environments; in 632 
short when regulation of invasion, replication and transmission processes is 633 
altered, virulence can emerge (71). Indeed, genome reduction via gene loss and 634 
pseudogenisation associated with enhanced pathogenicity has been described in 635 
other bacteria, such as Rickettsia spp., Shigella spp. and Yersinia spp. (71). 636 
Genome reduction through the loss of genes, potentially interfering with host 637 
infection, has also been proposed in S. suis (35). Therefore, as the elimination of 638 
the genetic marker associated with asymptomatic carriage from the GLM could 639 
not be done without a statistically significant loss of fit it was retained and its 640 
usefulness evaluated. 641 
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In conclusion, we foresee a useful clinical application of our pathotyping 642 
tool in preventative programs aimed at monitoring the health status of pigs and 643 
identification of subclinical carriers of invasive disease-associated S. suis strains 644 
in the upper respiratory tract. Our approach can easily be updated to incorporate 645 
global strain collections (such as, from North America and Southeast Asia) to 646 
identify geographically-dependent phenotypes. This could contribute to a lower 647 
prevalence of disease attributed to S. suis among pig populations and 648 
consequently a reduction in the usage of antibiotics in the swine industry, as well 649 
as a reduction in zoonotic transmission of this pathogen through improved 650 
surveillance of pig populations. 651 
  652 
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Figure 1. Agarose gel showing the expected amplicon sizes of our 932 
three genetic markers with the Streptococcus suis-specific marker from 14 933 
isolates of the training collection. Agarose gel containing multiplex-PCR 934 
amplicons produced from genomic DNA of eight invasive disease-associated, and 935 
six non-disease associated isolates of S. suis recovered from pigs on farms in 936 
England and Wales. PCR amplicons were electrophoresed on a 2% (wt/vol) 937 
agarose gel containing 1x SYBR Safe DNA gel stain for 60 minutes at a constant 938 
100 V and photographed under UV transillumination. Multiplex-PCR amplicon 939 
patterns matched anticipated amplicon patterns based on in silico analyses for all 940 
isolates described in this study. Isolate names are indicated above lanes. Lane M 941 
contains 1x Bioline HyperLadder 100 bp Plus DNA ladder with sizes indicated on 942 
the left (bp). Multiplex-PCR amplicon sizes are indicated on the right (bp). 943 
  944 
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Table 1. Multiplex-PCR primer details. Multiplex-PCR primers were 945 
designed using the online software primer3 (version 4.0.0, http://primer3.ut.ee) 946 
and designed to target conserved regions within the protein-encoding sequence 947 
of genetic markers (as opposed to flanking regions). Primers were designed to 948 
have similar physical characteristics, enabling simultaneous amplification under 949 
the same thermal cycling conditions and in multiplex reactions. GenBank 950 
identifier prefixes “SSU” and “SSUST3” correspond to Streptococcus suis P1/7 951 
(NC_012925) (32) and Streptococcus suis ST3 (NC_015433) (71) respectively. 952 
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Table 2. Contingency tables used to calculate the performance 955 
metrics summarising the classification of Streptococcus suis isolates in the 956 
out-of-sample test collection (n=50). Contingency tables used to calculate and 957 
summarise the performance metrics of two binary diagnostic tests. Each table 958 
compares the observed clinical phenotype (considered the ‘gold-standard’ in this 959 
study) to the use of the a) newly described pathotyping markers, b) serotypes: 1-960 
9 and 1/2, c) Virulence-associated markers: epf, mrp, and/or sly, d) Multilocus 961 
sequence type (MLST): 1, and e) assignment to Minimum Core Genome (MCG) 962 





    
 50 23 27   






19 19 0 1.00 0.00  
mPCR positive True positive False positive Positive predictive rate False discovery rate 
31 4 27 0.13 0.87 
mPCR negative False negative True negative False omission rate Negative predictive rate 
  0.83 0.00 0.90  
  True positive rate False positive rate F1 score  
  0.17 1.00   
  False negative rate True negative rate   
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 26 20 6 0.77 0.23 
Positive True positive False positive Positive predictive rate False discovery rate 
24 3 21 0.13 0.88 
Negative False negative True negative False omission rate Negative predictive rate 
  0.87 0.22 0.82  
  True positive rate False positive rate F1 score  
  0.13 0.78   
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 48 22 26 0.46 0.54 
Positive True positive False positive Positive predictive rate False discovery rate 
2 1 1 0.50 0.50 
Negative False negative True negative False omission rate Negative predictive rate 
  0.96 0.96 0.62  
  True positive rate False positive rate F1 score  
  0.04 0.04   
  False negative rate True negative rate   
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16 16 0 1.00 0.00 
Positive True positive False positive Positive predictive rate False discovery rate 
34 7 27 0.21 0.79 
Negative False negative True negative False omission rate Negative predictive rate 
  0.70 0.00 0.82  
  True positive rate False positive rate F1 score  
  0.30 1.00   
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18 18 0 1.00 0.00 
Positive True positive False positive Positive predictive rate False discovery rate 
32 5 27 0.16 0.84 
Negative False negative True negative False omission rate Negative predictive rate 
  0.78 0.00 0.  
  True positive rate False positive rate F1 score  
  0.22 1.00   
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Table 2. Contingency tables used to calculate the performance 
metrics summarising the classification of Streptococcus suis isolates in the 
out-of-sample test collection (n=50). Contingency tables used to calculate and 
summarise the performance metrics of two binary diagnostic tests. Each table 
compares the observed clinical phenotype (considered the Ǯgold-standardǯ in this 
study) to the use of the a) newly described pathotyping markers, b) serotypes: 1-
9 and 1/2, c) Virulence-associated markers: epf, mrp, and/or sly, d) Multilocus 
sequence type (MLST): 1, and e) assignment to Minimum Core Genome (MCG) 
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